Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Azvudine for COVID-19: real-time meta analysis of 18 studies

@CovidAnalysis, April 2024, Version 19V19
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen -12% 1.12 [0.05-23.9] recov. time 66 (n) 41 (n) Improvement, RR [CI] Treatment Control Chen 32% 0.68 [0.47-0.99] viral+ 166 (n) 41 (n) Han (PSM) 37% 0.63 [0.40-1.00] death 428 (n) 428 (n) Han (PSM) 3% 0.97 [0.83-1.14] no improv. 428 (n) 428 (n) Yang 91% 0.09 [0.01-1.62] death 0/317 6/487 Yang (PSW) 75% 0.25 [0.06-0.98] hosp. 317 (n) 487 (n) Yang (PSW) 16% 0.84 [0.65-1.09] no recov. 317 (n) 487 (n) Wang 20% 0.80 [0.46-1.40] death 128 (n) 55 (n) Wang 3% 0.97 [0.58-1.61] progression 128 (n) 55 (n) Jin -1% 1.01 [0.91-1.12] recov. time 33 (n) 33 (n) Shen (PSM) 74% 0.26 [0.07-0.94] death 3/226 10/226 Shen (PSM) 91% 0.09 [0.01-1.63] ventilation 0/226 5/226 Shen (PSM) 75% 0.25 [0.03-2.22] ICU 1/226 4/226 Shen (PSM) 57% 0.43 [0.18-0.99] progression 8/226 17/226 Chen (PSM) 6% 0.94 [0.61-1.43] death 29/99 31/99 Chen (PSM) 63% 0.37 [0.18-0.77] death 99 (n) 99 (n) Sun 54% 0.46 [0.15-1.34] death 5/245 9/245 Sun 0% 1.00 [0.14-7.04] ventilation 2/245 2/245 Sun -100% 2.00 [0.18-21.9] ICU 2/245 1/245 Sun 38% 0.62 [0.34-1.12] oxygen 16/245 26/245 Sun 48% 0.52 [0.30-0.90] progression 17/245 31/245 Zong (PSM) 62% 0.38 [0.23-0.62] death 195 (n) 390 (n) Shao 56% 0.44 [0.24-0.79] death 177 (n) 509 (n) Dian (PSM) 64% 0.36 [0.12-1.13] death 4/228 11/228 OT​1 Dian (PSM) 67% 0.33 [0.07-1.63] ventilation 2/228 6/228 OT​1 Dian (PSM) 0% 1.00 [0.06-15.9] ICU 1/228 1/228 OT​1 Dian (PSM) 48% 0.52 [0.29-0.92] progression 16/228 31/228 OT​1 Dian (PSM) 44% 0.56 [0.30-1.02] progression 15/228 27/228 OT​1 Zhou 22% 0.78 [0.56-1.09] death 37/131 69/191 Wei -0% 1.00 [0.68-1.47] death 63/461 36/264 OT​1 Wei 28% 0.72 [0.54-0.98] ventilation 77/461 61/264 OT​1 Wei 55% 0.45 [0.20-1.02] ICU 11/461 14/264 OT​1 Wei 22% 0.78 [0.60-1.01] progression 98/461 72/264 OT​1 de Souza (DB RCT) 27% 0.73 [0.17-3.15] ICU 3/91 4/88 de Souza (DB RCT) 42% 0.58 [0.14-2.36] no disch. 3/91 5/88 de Souza (DB RCT) 82% 0.18 [0.05-0.71] no recov. 91 (n) 88 (n) de Souza (DB RCT) 13% 0.87 [0.77-0.99] viral time 91 (n) 88 (n) Liu 24% 0.76 [0.42-1.37] progression 12/126 56/446 Li (PSM) 29% 0.71 [0.52-0.97] death 1,103 (n) 1,103 (n) Li 50% 0.50 [0.10-2.58] ICU 2/42 4/42 Li 11% 0.89 [0.73-1.09] hosp. time 42 (n) 42 (n) Li 50% 0.50 [0.27-0.94] viral+ 42 (n) 42 (n) Li 32% 0.68 [0.41-1.12] viral+ 15/42 22/42 Zhong (PSW) 35% 0.65 [0.42-1.00] death 1,490 (n) 1,373 (n) Zhong (PSW) 52% 0.48 [0.31-0.75] death 1,490 (n) 1,373 (n) Zhong (PSW) 87% 0.13 [0.06-0.25] death 1,490 (n) 1,373 (n) Azvudine COVID-19 outcomes c19early.org April 2024 1 OT: comparison with other treatment Favors azvudine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit